Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced the Phase I clinical study assessing Inovio's PENNVAX™-B DNA vaccine delivered using its proprietary electroporation technology in...